Review Reports
- Krishnendu Adhikary 1,2,*,
- Thirtsha Shohani Godwin 3 and
- Rajkumar Maiti 9,*
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsUpon reviewing the manuscript, I believe it is necessary to suggest modifications to general aspects rather than specific ones. I think that modifications to the content and structure of the manuscript are needed, rather than isolated changes.
The manuscript contains a considerable amount of information and an extensive bibliography; however, it lacks a scientific narrative or a clearly structured guiding thread. Throughout the text, the focus shifts constantly, making it difficult to identify the review's true main objective. It remains unclear whether the review is about quinones as antioxidants, as antidiabetic agents, pharmaceutical development, delivery systems, medicinal chemistry, or diabetes complications. The manuscript attempts to address all these topics simultaneously and, as a result, loses focus. This also makes the reading tedious, as the reader must scroll through many pages before reaching the topic that likely sparked their interest. I believe it would be beneficial to define a central question or a clearly delimited objective in the introduction and build the rest of the manuscript around that idea.
Furthermore, the title promises a "Translational Pharmaceutical Perspective," but the content does not consistently maintain that focus. Much of the manuscript is dedicated to describing general aspects of chemical classification, biosynthesis, structural properties, and biological mechanisms that have already been extensively reviewed in the literature. In contrast, the truly pharmaceutical and translational aspects, such as formulation strategies, bioavailability, pharmacokinetic limitations, clinical development, regulatory challenges, and real possibilities for transfer to clinical practice, appear scattered and less in-depth. At several points, the article feels more like a general review of quinones than a translation-oriented pharmaceutical review.
Related to the above, the evidence is also not organized according to its strength. Throughout the article, results from in vitro studies, animal models, and clinical studies are mixed with virtually equal weight, without establishing a hierarchy that allows the reader to clearly differentiate which findings have clinical evidence and which remain exclusively in the experimental realm. This can lead to an overestimation of the therapeutic potential of some compounds. It would be advisable to organize the evidence progressively, clearly differentiating preclinical findings from those that already have clinical validation.
Another aspect that disrupts the flow of the manuscript is the inclusion of the "Limitations of Current Antibiotic Therapy" section within the introduction. The article begins by describing the pathophysiology of diabetes and the role of oxidative stress; however, it immediately shifts to a relatively lengthy discussion of antimicrobial resistance, biofilms, and the limitations of antibiotics. This transition feels abrupt and creates the impression that the manuscript will change focus to the treatment of infections or diabetic ulcers. The text then returns to the topic of quinones, making this section seem out of place. While the connection can be justified from the perspective of diabetic complications, I believe this content should be significantly reduced or integrated later into a specific section on therapeutic applications, rather than being included in the introduction.
The manuscript is excessively descriptive. In numerous sections, it simply lists studies and summarizes results, but rarely offers a critical analysis that would allow for interpretation of the available evidence. The discrepancies between studies, methodological limitations, potential biases, and the reasons why some compounds have shown promising results in experimental models without subsequently translating into clinical benefits are not sufficiently discussed. A review of this nature should provide a critical view of the literature, not merely an extensive compilation of publications.
There is a balance problem among the different sections. Some sections, such as chemical classification, biosynthesis, and structural modifications, present a considerably greater level of detail than necessary to support the article's main message, while aspects of greater clinical relevance receive much less attention. Consequently, the review loses dynamism, and truly novel information is diluted among numerous general background references.
The manuscript devotes a significant amount of space to describing known properties of different quinones but does not establish comparisons between them. The reader ends up with an extensive list of compounds and mechanisms, although it is difficult to identify which ones represent the most promising candidates; which ones present the best evidence of efficacy, which ones have the greatest pharmacokinetic limitations, or which ones face significant safety concerns? A critical comparison between the main compounds would provide far greater value than an individual description of each.
An integrative synthesis is lacking at the end of the main sections. After reviewing multiple mechanisms, chemical families, or pharmacological properties, the text immediately moves on to the next section without offering an interpretation that helps the reader understand the relevance of the information presented. The review would be greatly enhanced if the key ideas were summarized at the end of each section and an explanation was given of how this information contributes to the development of quinones as potential therapeutic agents.
Although there are several figures of good graphic quality, many of them primarily serve an illustrative function and contain already known information. It would be much more useful to incorporate comparative tables summarizing the available clinical evidence for each quinone, the level of evidence, the main pharmacological limitations, the predominant mechanisms, and the current state of development. This type of resource would greatly facilitate consultation of the manuscript and increase its value as a review.
Regarding the Graphical Abstract, I would recommend modifying the statement related to protection against diabetes complications. Currently, the figure conveys the idea that quinones confer protection against these complications, when in reality much of the evidence remains experimental. It would be more appropriate to use terms such as "potential protection," "possible protection," or "probable protective effects," avoiding presenting as established something that has not yet been clinically demonstrated.
In Figure 1 and the other figures, I believe it is necessary to include the corresponding bibliographic references within the legend. The figure summarizes epidemiological data, pathophysiological mechanisms, and complications of diabetes, but the reader has no way of identifying the sources used to construct this synthesis. Incorporating the references in the legend would increase transparency and facilitate the verification of the information presented. Similarly, it would be beneficial for the figures not only to summarize general concepts but also to provide greater analytical value to the manuscript, for example, by comparing mechanisms, levels of evidence, or pharmaceutical strategies among the different types of quinones.
Overall, I believe the manuscript's main problem is not a lack of information, but rather an excess of poorly organized content. The review needs a thorough reorganization to define a clear objective, reduce encyclopedic information, strengthen critical analysis, and focus the discussion on those aspects that truly justify the translational approach announced in the title. Only then will the manuscript be able to convey a solid message and maintain the reader's interest throughout the review.
After reading a review like this, I would like it to be clear which compounds—some of which are already commercially available, are effective, what they are effective for, and how well-founded their use is, all of this explained clearly.
Author Response
Reviewer 1 Comments:
- Upon reviewing the manuscript, I believe it is necessary to suggest modifications to general aspects rather than specific ones. I think that modifications to the content and structure of the manuscript are needed, rather than isolated changes.
- The manuscript contains a considerable amount of information and an extensive bibliography; however, it lacks a scientific narrative or a clearly structured guiding thread. Throughout the text, the focus shifts constantly, making it difficult to identify the review's true main objective. It remains unclear whether the review is about quinones as antioxidants, as antidiabetic agents, pharmaceutical development, delivery systems, medicinal chemistry, or diabetes complications. The manuscript attempts to address all these topics simultaneously and, as a result, loses focus. This also makes the reading tedious, as the reader must scroll through many pages before reaching the topic that likely sparked their interest. I believe it would be beneficial to define a central question or a clearly delimited objective in the introduction and build the rest of the manuscript around that idea.
Response to the Reviewer: We sincerely thank you for this valuable comment. We have reduced the extensive bibliography and revised the manuscript by removing unnecessary information and trimming content that was not directly aligned with the central theme. These revisions have improved the focus, coherence, and overall readability of the manuscript.
- Furthermore, the title promises a "Translational Pharmaceutical Perspective," but the content does not consistently maintain that focus. Much of the manuscript is dedicated to describing general aspects of chemical classification, biosynthesis, structural properties, and biological mechanisms that have already been extensively reviewed in the literature. In contrast, the truly pharmaceutical and translational aspects, such as formulation strategies, bioavailability, pharmacokinetic limitations, clinical development, regulatory challenges, and real possibilities for transfer to clinical practice, appear scattered and less in-depth. At several points, the article feels more like a general review of quinones than a translation-oriented pharmaceutical review.
Response to the Reviewer: We have reduced the general information on quinone chemistry and biological mechanisms and strengthened the discussion of pharmaceutical and translational aspects, including formulation, bioavailability, pharmacokinetics, clinical development, and regulatory challenges, to ensure a more consistent translational focus.
- Related to the above, the evidence is also not organized according to its strength. Throughout the article, results from in vitro studies, animal models, and clinical studies are mixed with virtually equal weight, without establishing a hierarchy that allows the reader to clearly differentiate which findings have clinical evidence and which remain exclusively in the experimental realm. This can lead to an overestimation of the therapeutic potential of some compounds. It would be advisable to organize the evidence progressively, clearly differentiating preclinical findings from those that already have clinical validation.
Response to the Reviewer: We have reorganized the evidence according to its strength by clearly distinguishing in vitro, in vivo, and clinical findings, with greater emphasis on clinically validated evidence. This revision helps provide a clearer and more balanced assessment of the therapeutic potential of quinones.
- Another aspect that disrupts the flow of the manuscript is the inclusion of the "Limitations of Current Antibiotic Therapy" section within the introduction. The article begins by describing the pathophysiology of diabetes and the role of oxidative stress; however, it immediately shifts to a relatively lengthy discussion of antimicrobial resistance, biofilms, and the limitations of antibiotics. This transition feels abrupt and creates the impression that the manuscript will change focus to the treatment of infections or diabetic ulcers. The text then returns to the topic of quinones, making this section seem out of place. While the connection can be justified from the perspective of diabetic complications, I believe this content should be significantly reduced or integrated later into a specific section on therapeutic applications, rather than being included in the introduction.
Response to the Reviewer: We have completely removed the “Limitations of Current Antibiotic Therapy” section, as it was not directly relevant to the central focus of our review. This revision has improved the logical flow and focus of the Introduction.
- The manuscript is excessively descriptive. In numerous sections, it simply lists studies and summarizes results, but rarely offers a critical analysis that would allow for interpretation of the available evidence. The discrepancies between studies, methodological limitations, potential biases, and the reasons why some compounds have shown promising results in experimental models without subsequently translating into clinical benefits are not sufficiently discussed. A review of this nature should provide a critical view of the literature, not merely an extensive compilation of publications.
Response to the Reviewer: We agree with the reviewer and have reduced the extensive descriptive information on quinones while strengthening the critical discussion of the available evidence. However, detailed translational and clinical evidence on quinones remains limited in the literature. Therefore, we have revised the manuscript to critically discuss the available translational evidence and clearly acknowledge the current limitations in translating experimental findings into clinical benefits.
- There is a balance problem among the different sections. Some sections, such as chemical classification, biosynthesis, and structural modifications, present a considerably greater level of detail than necessary to support the article's main message, while aspects of greater clinical relevance receive much less attention. Consequently, the review loses dynamism, and truly novel information is diluted among numerous general background references.
Response to the Reviewer: We have improved the balance among the different sections by reducing unnecessary details in the chemical classification, biosynthesis, and structural modification sections and strengthening the discussion of clinically relevant aspects. This revision has helped maintain a clearer focus on the main message of the review.
- The manuscript devotes a significant amount of space to describing known properties of different quinones but does not establish comparisons between them. The reader ends up with an extensive list of compounds and mechanisms, although it is difficult to identify which ones represent the most promising candidates; which ones present the best evidence of efficacy, which ones have the greatest pharmacokinetic limitations, or which ones face significant safety concerns? A critical comparison between the main compounds would provide far greater value than an individual description of each.
Response to the Reviewer: We agree that a comparative evaluation of the major quinone compounds would enhance the value of the review. Accordingly, we have revised the manuscript to provide a more comparative discussion based on the available evidence. However, detailed and consistent comparative studies for individual quinones remain limited in the literature. Therefore, we have highlighted the available evidence and clearly acknowledged this limitation while avoiding overinterpretation of the current data.
- An integrative synthesis is lacking at the end of the main sections. After reviewing multiple mechanisms, chemical families, or pharmacological properties, the text immediately moves on to the next section without offering an interpretation that helps the reader understand the relevance of the information presented. The review would be greatly enhanced if the key ideas were summarized at the end of each section and an explanation was given of how this information contributes to the development of quinones as potential therapeutic agents.
Response to the Reviewer: We have incorporated brief integrative summaries at the end of the major sections to highlight the key findings and their relevance to the therapeutic development of quinones. These additions provide a clearer connection between the discussed evidence and the overall objective of the review.
- Although there are several figures of good graphic quality, many of them primarily serve an illustrative function and contain already known information. It would be much more useful to incorporate comparative tables summarizing the available clinical evidence for each quinone, the level of evidence, the main pharmacological limitations, the predominant mechanisms, and the current state of development. This type of resource would greatly facilitate consultation of the manuscript and increase its value as a review.
Response to the Reviewer: We have revised the manuscript by incorporating comparative tables summarizing the available evidence for the major quinones, including their pharmacological activities, mechanisms, limitations, and current developmental status. As clinical evidence for individual quinones remains limited, the tables have been prepared based on the available preclinical and clinical evidence to provide a clearer and more useful comparison.
- Regarding the Graphical Abstract, I would recommend modifying the statement related to protection against diabetes complications. Currently, the figure conveys the idea that quinones confer protection against these complications, when in reality much of the evidence remains experimental. It would be more appropriate to use terms such as "potential protection," "possible protection," or "probable protective effects," avoiding presenting as established something that has not yet been clinically demonstrated.
Response to the Reviewer: We are thankful to the reviewer for this constructive comment. We have revised the graphical abstract as per reviewers instructions.
- In Figure 1 and the other figures, I believe it is necessary to include the corresponding bibliographic references within the legend. The figure summarizes epidemiological data, pathophysiological mechanisms, and complications of diabetes, but the reader has no way of identifying the sources used to construct this synthesis. Incorporating the references in the legend would increase transparency and facilitate the verification of the information presented. Similarly, it would be beneficial for the figures not only to summarize general concepts but also to provide greater analytical value to the manuscript, for example, by comparing mechanisms, levels of evidence, or pharmaceutical strategies among the different types of quinones.
Response to the Reviewer: Thank you for this valuable observation. We agree that the scientific basis of the information presented in the figures should be transparent and verifiable. We clarify that the figures were AI-assisted graphical illustrations created by the authors, and the AI tool was used only for visual composition and illustration; it was not used as a source of scientific information or references. To address this concern, we have revised the figure legends to include the appropriate bibliographic references for the scientific information represented in each figure.
- Overall, I believe the manuscript's main problem is not a lack of information, but rather an excess of poorly organized content. The review needs a thorough reorganization to define a clear objective, reduce encyclopedic information, strengthen critical analysis, and focus the discussion on those aspects that truly justify the translational approach announced in the title. Only then will the manuscript be able to convey a solid message and maintain the reader's interest throughout the review.
Response to the Reviewer: We have reduced redundant information, reorganized the content to establish a clear and coherent narrative, strengthened the critical analysis of the available evidence, and focused the discussion around a clear central message with greater emphasis on its translational relevance.
- After reading a review like this, I would like it to be clear which compounds—some of which are already commercially available- are effective, what they are effective for, and how well-founded their use is, all of this explained clearly.
Response to the Reviewer: we have revised the manuscript to more clearly highlight the key bioactive compounds, their reported therapeutic effects, and the strength of the available evidence supporting their potential use. Where applicable, we have also emphasized compounds that are already commercially available and clarified their translational relevance, thereby providing readers with a clearer understanding of which compounds are effective, for which applications, and how well supported their use is by the current evidence.
Author Response File:
Author Response.docx
Reviewer 2 Report
Comments and Suggestions for AuthorsDear Dr. Adhikary,
I have an honor to review your manuscript named “Translational Pharmaceutical Perspectives on Quinones as Antioxidant and Antidiabetic Agents in Diabetes and Its Complications.”
Your work is devoted to an overview of the properties of an extensive class of chemicals - quinones, and to discuss the possibilities of their use as antioxidants and antidiabetic agents.
When reading the manuscript, I had a number of questions and comments.
- The amount of work seems too much for the article and for the review. The 83 pages probably correspond more to the dimensions of a chapter in a book than an individual article.
- In my opinion, there is a lot of excessive, well-known information - about the enzymes of the antioxidant system, about the regulation of insulin secretion, about the complications of diabetes, etc. This information significantly overloads the article, leads to numerous repetitions and makes it difficult to perceive the text.
- Some of the information does not correspond to the goals and title of the work - for example, paragraph 1.3. - Limitations of current antibiotic therapy, paragraph 6.1 - endogenic quinones and others.
- There are a lot of typos (Line 751, 843 etc.), sometimes they even distort the meaning of the text, for example Line 529, 563-566, 578-579, 583, 837, 853-854, 1709 etc.
- There are many errors in the English language and style, they sometimes distort the meaning of the text, for example, line 471 (using glutathione by reducing glutathione), line 1121 (six members..., and only five are listed below), line 1371 modin methylether(?) (may be you mean emodin-3-methyl ether?), line 1777 (what kind of barriers?), 1778 (human evidence?).
- A huge number of links are presented, while there are works 10-15 years ago, while in some places of the text few links are made or they are repeated several times (for example, link 39, lines 250-269, lines 315-333; links 50-52), which raises questions about the scientific novelty of these parts of the article.
- There are errors in references when you refer to a fundamentally important term, but to a secondary article where it is mentioned outside the main context, in addition, this is accompanied by errors in the text and style (for example, reference 92, lines 527-530) - it is not clear whether this is a mistake, typo, or insufficient analysis of the literature in this context.
- Redundant information is also duplicated by large tables - it seems appropriate to revise and shorten the text, put the tables in Supplement (Appendix) Form to the article.
- The paper contains drawings created using AI. The reference to the use of AI is not appropriate in the text of the article itself, but at the end or in the appendix. In addition, drawings have an illustrative, popular science meaning rather than carrying a scientific burden.
- The rules for the presentation of abbreviations are not fully observed - some abbreviations are included in the general list at the end of the article (for example, GLUT 4), some (GLUT 2) are not, there is no uniformity in the presentation of the same abbreviations, sometimes they are possibly confusing (for example, Line 635, 636, 645 and 657 - different abbreviations of the name of the same biochemical path).
- It is fundamentally important that the work contains terminologically controversial/erroneous concepts that need to be clarified/corrected. For example, a very generalized statement in line 419 that physiological processes (respiration, food, metabolism) can generate reactive forms of oxygen and nitrogen - based on deep oxidation mechanisms, loss of electrons in the respiratory chain of mitochondria, etc., and talking in general about the process of respiration and digestion - seems to be highly generalized. A more accurate definition of oxidative stress is needed (line 422) - there is a generally accepted definition that takes into account not only the processes of oxidative damage due to an imbalance of oxidants and antioxidants, but also a violation of redox regulation, the use of the term antioxidant activity as colloquial, although this is a fairly clear chemical concept, erroneous (a widely used mistake) the name of antioxidant enzymes (line 467) - they do not have antioxidant properties directly, but catalyze various reactions that directly or indirectly affect the severity of oxidative stress - you yourself write about this in your work, “antioxidant” genes - line 515.
- Some data do not correspond in meaning to the place in the text - for example, in paragraph 6.2 of Nutraceutical Quinones, in lines 1119-1127, you turn to the description of anthracycline anticancer drugs that are produced either by biosynthesis or by complete chemical synthesis and have no direct relation to Nutraceutical Quinones.
I believe that before accepting your work for publication as a review, it is necessary to significantly reduce the volume of text, remove repetitions, optimize/put tables in the appendix, check the correspondence of links to the text, reduce the number of references, revise the data of the scientific literature in favor of newer data there, where possible and appropriate, check the text carefully for typographical errors, spelling errors, repetitions, English grammar, compliance with the title and objectives of the review, and the titles and structure of individual paragraphs. After eliminating these comments, the work can be submitted for re-review.
Author Response
Reviewer 2 Comments:
Dear Dr. Adhikary,
I have an honor to review your manuscript named “Translational Pharmaceutical Perspectives on Quinones as Antioxidant and Antidiabetic Agents in Diabetes and Its Complications.”
Your work is devoted to an overview of the properties of an extensive class of chemicals - quinones, and to discuss the possibilities of their use as antioxidants and antidiabetic agents.
When reading the manuscript, I had a number of questions and comments.
- The amount of work seems too much for the article and for the review. The 83 pages probably correspond more to the dimensions of a chapter in a book than an individual article.
Response to the Reviewer:
We sincerely thank the Reviewer for this valuable observation. We agree that the original manuscript was overly extensive for a review article. In response, we have streamlined the manuscript, removed repetitive and less essential material, and focused the discussion on the pharmaceutical relevance of quinones in diabetes, including their mechanisms, therapeutic potential, clinical evidence, limitations, and future directions. We believe these revisions have substantially improved the focus, readability, and suitability of the manuscript as a review article.
- In my opinion, there is a lot of excessive, well-known information - about the enzymes of the antioxidant system, about the regulation of insulin secretion, about the complications of diabetes, etc. This information significantly overloads the article, leads to numerous repetitions and makes it difficult to perceive the text.
Response to the Reviewer
We sincerely thank the Reviewer for this constructive comment. We agree that some background information was more extensive than necessary and resulted in repetition. Accordingly, we have substantially condensed the general discussion of antioxidant enzymes, insulin secretion, and diabetic complications, and have retained only the information directly relevant to the role and therapeutic potential of quinones. These revisions have reduced repetition and improved the overall flow, focus, and readability of the manuscript.
- Some of the information does not correspond to the goals and title of the work - for example, paragraph 1.3. - Limitations of current antibiotic therapy, paragraph 6.1 - endogenic quinones and others.
Response to the Reviewer:
We sincerely thank the Reviewer for pointing this out. We agree that some of the earlier content was broader than necessary and could distract from the central focus of the review, which is the pharmaceutical and therapeutic relevance of quinones in diabetes and its complications. The original material has therefore been carefully reassessed and streamlined. In particular, the discussion of limitations of current antibiotic therapy has been removed because it does not directly contribute to the objectives of the present review. The discussion of endogenous quinones has also been substantially condensed and retained only where it is directly relevant to the pharmacological rationale, biological function, therapeutic development, or clinical relevance of compounds such as CoQ10 and vitamin K. The manuscript now places greater emphasis on quinone chemistry, redox activity, antidiabetic mechanisms, diabetic complications, pharmacokinetic and formulation considerations, and the strength of available clinical evidence, which are consistent with the stated objectives and title of the review. We have also removed or shortened other peripheral background material and eliminated overlapping discussions. This revision has helped us maintain the breadth necessary for a pharmaceutical review while keeping the manuscript focused specifically on quinones as antioxidant and antidiabetic agents in diabetes and its complications. We appreciate the Reviewer’s comment, which has helped us improve the relevance, focus, and overall coherence of the manuscript.
- There are a lot of typos (Line 751, 843 etc.), sometimes they even distort the meaning of the text, for example Line 529, 563-566, 578-579, 583, 837, 853-854, 1709 etc.
Response to the Reviewer:
We sincerely thank the Reviewer for bringing these errors to our attention. We have carefully proofread the entire manuscript and corrected the typographical, grammatical, spacing, and formatting errors, particularly at the lines highlighted by the Reviewer (Lines 529, 563–566, 578–579, 583, 751, 837, 843, 853–854, 1709, and others). Particular attention was given to errors that could alter or obscure the intended scientific meaning. We have also checked the revised text for consistency in terminology, abbreviations, units, and sentence structure. We appreciate this comment, which has helped us improve the accuracy, clarity, and overall presentation of the manuscript.
- There are many errors in the English language and style, they sometimes distort the meaning of the text, for example, line 471 (using glutathione by reducing glutathione), line 1121 (six members..., and only five are listed below), line 1371 modin methylether(?) (may be you mean emodin-3-methyl ether?), line 1777 (what kind of barriers?), 1778 (human evidence?).
Response to the Reviewer:
We sincerely thank the Reviewer for highlighting these language and style issues. We have carefully revised the manuscript to correct grammatical errors, unclear expressions, and inconsistencies that could affect the intended meaning. In particular, the statements at Lines 471, 1121, 1371, 1777, and 1778 have been carefully reviewed and corrected. We have also verified the terminology, compound names, numerical descriptions, and scientific wording throughout the manuscript. Where the original wording was ambiguous, we have rewritten the relevant sentences to make the intended meaning clear and precise. We believe these revisions have substantially improved the language, readability, and scientific clarity of the manuscript.
- A huge number of links are presented, while there are works 10-15 years ago, while in some places of the text few links are made or they are repeated several times (for example, link 39, lines 250-269, lines 315-333; links 50-52), which raises questions about the scientific novelty of these parts of the article.
Response to the Reviewer:
We sincerely thank the Reviewer for this important observation. We have carefully revised the reference list and citation pattern throughout the manuscript. Repeated citations have been reduced, unnecessary references removed, and more recent and relevant studies incorporated where available. Older references have been retained only when they provide essential or foundational evidence. We have also strengthened citation support for key mechanistic and therapeutic claims and clarified the distinction between established findings and emerging evidence. These revisions have improved the balance, relevance, and scientific focus of the review.
- There are errors in references when you refer to a fundamentally important term, but to a secondary article where it is mentioned outside the main context, in addition, this is accompanied by errors in the text and style (for example, reference 92, lines 527-530) - it is not clear whether this is a mistake, typo, or insufficient analysis of the literature in this context.
Response to the Reviewer:
We sincerely thank the Reviewer for identifying this important issue. We have carefully re-examined the cited literature, particularly Reference 92 and the discussion around Lines 527–530, and corrected the citation and accompanying text to ensure that the reference directly supports the statement being made. We have also reviewed the surrounding sections to identify similar citation mismatches, typographical errors, and unclear wording. These corrections have improved the accuracy, consistency, and reliability of the literature-supported statements throughout the manuscript.
- Redundant information is also duplicated by large tables - it seems appropriate to revise and shorten the text, put the tables in Supplement (Appendix) Form to the article.
Response to the Reviewer:
We sincerely thank the Reviewer for this constructive suggestion. We agree that some information presented in the tables overlaps with the main text. Accordingly, we have shortened and streamlined the corresponding text and removed repetitive explanations. To improve readability and maintain the focus of the main article, the detailed tables 3 and 4 have been moved to the Supplementary/Appendix section, while only the most relevant findings are retained in the main text. These revisions have reduced redundancy and improved the overall clarity and flow of the manuscript.
- The paper contains drawings created using AI. The reference to the use of AI is not appropriate in the text of the article itself, but at the end or in the appendix. In addition, drawings have an illustrative, popular science meaning rather than carrying a scientific burden.
Response to the Reviewer:
We sincerely thank the Reviewer for this important observation. We agree that the figures should provide clear scientific value rather than serve merely as illustrative material. Accordingly, we have revised the figures to emphasize the mechanistic and pharmaceutical aspects of quinones in diabetes. Non-essential illustrative elements have been removed or simplified. We have also relocated the statement regarding the use of AI-assisted tools for figure preparation from the main text to Acknowledgement section, in accordance with the journal’s reporting requirements.
- The rules for the presentation of abbreviations are not fully observed - some abbreviations are included in the general list at the end of the article (for example, GLUT 4), some (GLUT 2) are not, there is no uniformity in the presentation of the same abbreviations, sometimes they are possibly confusing (for example, Line 635, 636, 645 and 657 - different abbreviations of the name of the same biochemical path).
Response to the Reviewer:
We sincerely thank the Reviewer for identifying this inconsistency. We agree that the abbreviation format was not fully uniform in the previous version. We have therefore systematically checked the manuscript and revised the abbreviation presentation throughout. In particular, GLUT4 and GLUT2, as well as pathway-related abbreviations such as PI3K/Akt, AMPK, and related signalling terms, have been standardized. The abbreviation list has also been cross-checked against the main text to ensure that all frequently used abbreviations are included, defined consistently at first use, and presented in the same format throughout the manuscript. For example, the revised text now uses GLUT4 and GLUT2 consistently rather than alternating between forms such as “GLUT 4” and “GLUT-4.”
- It is fundamentally important that the work contains terminologically controversial/erroneous concepts that need to be clarified/corrected. For example, a very generalized statement in line 419 that physiological processes (respiration, food, metabolism) can generate reactive forms of oxygen and nitrogen - based on deep oxidation mechanisms, loss of electrons in the respiratory chain of mitochondria, etc., and talking in general about the process of respiration and digestion - seems to be highly generalized. A more accurate definition of oxidative stress is needed (line 422) - there is a generally accepted definition that takes into account not only the processes of oxidative damage due to an imbalance of oxidants and antioxidants, but also a violation of redox regulation, the use of the term antioxidant activity as colloquial, although this is a fairly clear chemical concept, erroneous (a widely used mistake) the name of antioxidant enzymes (line 467) - they do not have antioxidant properties directly, but catalyze various reactions that directly or indirectly affect the severity of oxidative stress - you yourself write about this in your work, “antioxidant” genes - line 515.
Response to the Reviewer:
We sincerely thank the Reviewer for this valuable observation. We agree that several statements and terms required greater precision. We have revised the relevant sections to provide a more accurate definition of oxidative stress, clarify the specific sources and mechanisms of ROS/RNS generation, and distinguish oxidative stress from normal redox processes. We have also replaced imprecise use of “antioxidant activity” where necessary and revised “antioxidant enzymes” to enzymes involved in antioxidant defence and redox homeostasis, reflecting their actual catalytic roles. Related terminology, including “antioxidant genes,” has also been standardized throughout the manuscript.
- Some data do not correspond in meaning to the place in the text - for example, in paragraph 6.2 of Nutraceutical Quinones, in lines 1119-1127, you turn to the description of anthracycline anticancer drugs that are produced either by biosynthesis or by complete chemical synthesis and have no direct relation to Nutraceutical Quinones.
Response to the Reviewer:
We sincerely thank the Reviewer for identifying this inconsistency. We agree that the discussion of anthracyclines within Section 6.2, “Nutraceutical Quinones,” was not appropriately positioned and could create confusion between nutraceutical quinones and clinically used anthracycline anticancer agents. The relevant passage has therefore been removed from Section 6.2, and the discussion has been restricted to quinones with nutritional or nutraceutical relevance and their evidence in diabetes. This correction also helps maintain the manuscript's central focus on the pharmaceutical and therapeutic potential of quinones in diabetes and its complications. The revised manuscript now avoids presenting anthracyclines as nutraceutical candidates.
I believe that before accepting your work for publication as a review, it is necessary to significantly reduce the volume of text, remove repetitions, optimize/put tables in the appendix, check the correspondence of links to the text, reduce the number of references, revise the data of the scientific literature in favor of newer data there, where possible and appropriate, check the text carefully for typographical errors, spelling errors, repetitions, English grammar, compliance with the title and objectives of the review, and the titles and structure of individual paragraphs. After eliminating these comments, the work can be submitted for re-review.
Response to the Reviewer:
We sincerely thank the Reviewer for overall concern to and the valuable suggestion to reduce the volume of text and eliminate repetitive content. We agree with the Reviewer and have substantially revised and condensed the manuscript accordingly. Repetitive and non-essential material has been removed, and the discussion has been focused more specifically on the pharmaceutical relevance of the topic.
We have also carefully edited the manuscript to improve the language, terminology, clarity, and overall readability. Unnecessary references have been removed, and the remaining references have been reviewed for relevance. In addition, typographical errors, grammatical inconsistencies, abbreviations, and other editorial issues have been corrected throughout the revised manuscript.
Author Response File:
Author Response.docx
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsThe new version shows significant improvement over the previous one, particularly regarding the manuscript's organization, the distinction between preclinical and clinical evidence, and the pharmaceutical and translational focus. My previous comments have been adequately addressed.
I suggest only a few minor corrections prior to publication:
The study's objective is clearly stated in the abstract. However, I believe it would be beneficial to include a brief sentence at the end of the Introduction that directly states the review's main objective. This would help conclude the introduction and maintain a clear focus on the manuscript's scope from the outset.
Tone down certain statements in Section 9. This section still contains assertions that could be interpreted as implying stronger clinical evidence than is actually available, particularly when discussing the benefits of quinones in general or potential advantages over conventional antidiabetic treatments. This contrasts somewhat with Section 7 and Table 3, where the authors correctly acknowledge that CoQ10 is supported by more robust evidence in humans, whereas evidence for several other quinones remains primarily preclinical. I suggest simply adjusting the wording of these statements to ensure the claims align with the actual evidence.
There are some instances of repetitive or incomplete sentences, or sentences with phrasing that could be improved; please review these.
Author Response
Reviewer 1 Comments:
The new version shows significant improvement over the previous one, particularly regarding the manuscript's organization, the distinction between preclinical and clinical evidence, and the pharmaceutical and translational focus. My previous comments have been adequately addressed.
I suggest only a few minor corrections prior to publication:
The study's objective is clearly stated in the abstract. However, I believe it would be beneficial to include a brief sentence at the end of the Introduction that directly states the review's main objective. This would help conclude the introduction and maintain a clear focus on the manuscript's scope from the outset.
Response to Reviewer Comment
We sincerely thank the reviewer for this helpful suggestion. We agree that an explicit statement of the review objective at the end of the Introduction would provide a clearer transition from the background and rationale to the scope of the review. Accordingly, we have added a concise objective paragraph at the end of Section 1.4. The revised text clarifies that the review critically examines the pharmaceutical potential of quinones in diabetes and its complications, with emphasis on their chemical diversity, redox-dependent mechanisms, structure–activity relationships, pharmacokinetic and formulation challenges, and the distinction between preclinical and clinical evidence.
Tone down certain statements in Section 9. This section still contains assertions that could be interpreted as implying stronger clinical evidence than is actually available, particularly when discussing the benefits of quinones in general or potential advantages over conventional antidiabetic treatments. This contrasts somewhat with Section 7 and Table 3, where the authors correctly acknowledge that CoQ10 is supported by more robust evidence in humans, whereas evidence for several other quinones remains primarily preclinical. I suggest simply adjusting the wording of these statements to ensure the claims align with the actual evidence.
Response to Reviewer Comment
We appreciate the reviewer for highlighting this important point. We agree that some statements in Section 9 could be interpreted as implying a greater level of clinical evidence than is currently available. We have therefore carefully revised Section 9 to distinguish evidence according to study design and compound-specific clinical maturity. Statements suggesting therapeutic advantages over conventional antidiabetic treatments have been removed. The revised section now emphasises that CoQ10 has the most substantial human evidence, whereas evidence for TQ, PQQ, anthraquinones and other quinone derivatives remains heterogeneous and is predominantly preclinical or indirect. We have also clarified that observational findings do not establish therapeutic efficacy and that quinones should currently be considered investigational or potential adjunctive approaches rather than replacements for established antidiabetic therapies.
In addition, we reviewed Table 3 to ensure that its wording is consistent with the evidence hierarchy presented.
There are some instances of repetitive or incomplete sentences, or sentences with phrasing that could be improved; please review these.
Response to Reviewer Comment
We thank the reviewer for this observation. We have carefully proofread the manuscript and corrected repetitive, incomplete and awkwardly phrased sentences throughout the text. Particular attention was given to Section 1.2, where a duplicated sentence concerning ROS-mediated β-cell dysfunction was corrected, as well as Sections 8 and 8.1, where repetitive expressions and unclear constructions were revised for greater readability. The re-revised manuscript has also been checked for consistency in terminology, sentence structure and scientific tone.
Author Response File:
Author Response.docx
Reviewer 2 Report
Comments and Suggestions for AuthorsDear Dr. Adhikary,
I have an honor to review the revised version (Version 2) of your manuscript named “Translational Pharmaceutical Perspectives on Quinones as Antioxidant and Antidiabetic Agents in Diabetes and Its Complications.”
I have read your responses to my comments and regard them as comprehensive. Some points of the text may cause additional comments, for example, paragraph 3.2 of Antioxidant Enzyme uses controversial terminology, as indicated earlier, but in general this is not a critical error.
I also recommend putting absolutely all the abbreviations at the end of the text - due to the fact that the text is large, there may be difficulties when abbreviations reappear in the text - the search for the decoding of the abbreviation given in the text earlier can be difficult.
Overall, obvious adjustments and corrections were made to the manuscript. The text was improved by reducing irrelevant and irrelevant materials.
The manuscript, although it remains quite large in volume, has been significantly improved.
The review is of substantial interest to readers involved in the treatment of diabetes mellitus, antioxidant therapy, biochemistry and quinone pharmacology.
I believe that after minor improvements, your review may be recommended for publication.
Author Response
Reviewer 2 Comments:
Dear Dr. Adhikary,
I have an honor to review the revised version (Version 2) of your manuscript named “Translational Pharmaceutical Perspectives on Quinones as Antioxidant and Antidiabetic Agents in Diabetes and Its Complications.”
I have read your responses to my comments and regard them as comprehensive. Some points of the text may cause additional comments, for example, paragraph 3.2 of Antioxidant Enzyme uses controversial terminology, as indicated earlier, but in general this is not a critical error.
Response to Reviewer Comment
We thank the Reviewer for highlighting the terminology used in Section 3.2. We carefully reconsidered this subsection and agreed that several expressions required greater biochemical precision. Accordingly, we have completely revised Section 3.2, replacing the term “primary antioxidant enzymes” with “major antioxidant enzymes,” correcting the description of GPx, and standardizing the nomenclature and cellular localization of the SOD isoforms. We also removed an overly broad statement concerning SOD supplementation and clarified that the reported effects of quinones on antioxidant enzyme activity are predominantly supported by experimental studies. These revisions have improved the biochemical accuracy and scientific clarity of the section without altering the interpretation of the cited evidence.
I also recommend putting absolutely all the abbreviations at the end of the text - due to the fact that the text is large, there may be difficulties when abbreviations reappear in the text - the search for the decoding of the abbreviation given in the text earlier can be difficult.
Response to Reviewer Comment
We sincerely appreciate this practical suggestion. We have carefully rechecked the entire manuscript expanded the abbreviation list at the end of the re-revised manuscript.
Overall, obvious adjustments and corrections were made to the manuscript. The text was improved by reducing irrelevant and irrelevant materials.
Response to Reviewer Comment
We are grateful to the reviewer for recognizing the improvement aid to the manuscript.
The manuscript, although it remains quite large in volume, has been significantly improved.
The review is of substantial interest to readers involved in the treatment of diabetes mellitus, antioxidant therapy, biochemistry and quinone pharmacology.
I believe that after minor improvements, your review may be recommended for publication.
Response to Reviewer Comment
We sincerely thank the Reviewer for considering the revised manuscript to be substantially improved and for recognizing its potential interest to readers working in diabetes mellitus, antioxidant therapy, biochemistry, and quinone pharmacology. We have incorporated the suggested minor improvements and carefully proofread the revised manuscript to address remaining grammatical, terminological, and formatting issues.
We hope that the revisions satisfactorily address the Reviewer’s remaining concerns and that the manuscript is now suitable for publication in Pharmaceutics. We are grateful for the Reviewer’s constructive comments, which have helped us improve the scientific accuracy, clarity, and overall presentation of the manuscript.
Author Response File:
Author Response.docx